← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
TAI-GPC3-CART cells (TAI-GPC3-CART cells)
Shanghai GeneChem Co., Ltd.·Carcinoma, Hepatocellular
1 trials
Overview
Program
TAI-GPC3-CART cells
Overview
Company
Shanghai GeneChem Co., Ltd.
Overview
Modality
CGT
Overview
Target
Carcinoma, Hepatocellular
Overview
Indication
Carcinoma, Hepatocellular
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
De novo design of miniproteins targeting GPCRs.. G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development 1,2 , but the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic 3-6 . Here we describe computational de novo design methods and a high-throughpu…
Toxicology
CRS
Reported
Clinical
Safety signal
De novo design of miniproteins targeting GPCRs.. G protein-coupled receptors (GPCRs) play key roles in physiology and are central targets for drug discovery and development 1,2 , but the design of protein agonists and antagonists has been challenging as GPCRs are integral membrane proteins and conformationally dynamic 3-6 . Here we describe computational de novo design methods and a high-throughpu…
Clinical
Program phase
PHASE_2